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Background: Preeclampsia is one of the leading causes of fetal and maternal morbidity and mortality worldwide.
Preterm babies of mothers with early onset preeclampsia (EOPE) are at higher risks for various diseases later on in life,
including cardiovascular diseases. We hypothesized that genome-wide epigenetic alterations occur in cord blood DNAs
in association with EOPE and conducted a case control study to compare the genome-scale methylome differences in
cord blood DNAs between 12 EOPE-associated and 8 normal births.
Results: Bioinformatics analysis of methylation data from the Infinium HumanMethylation450 BeadChip shows a
genome-scale hypomethylation pattern in EOPE, with 51,486 hypomethylated CpG sites and 12,563 hypermethylated sites
(adjusted P <0.05). A similar trend also exists in the proximal promoters (TSS200) associated with protein-coding genes.
Using summary statistics on the CpG sites in TSS200 regions, promoters of 643 and 389 genes are hypomethylated and
hypermethylated, respectively. Promoter-based differential methylation (DM) analysis reveals that genes in the farnesoid X
receptor and liver X receptor (FXR/LXR) pathway are enriched, indicating dysfunction of lipid metabolism in cord blood
cells. Additional biological functional alterations involve inflammation, cell growth, and hematological system
development. A two-way ANOVA analysis among coupled cord blood and amniotic membrane samples shows
that a group of genes involved in inflammation, lipid metabolism, and proliferation are persistently differentially
methylated in both tissues, including IL12B, FAS, PIK31, and IGF1.
Conclusions: These findings provide, for the first time, evidence of prominent genome-scale DNA methylation
modifications in cord blood DNAs associated with EOPE. They may suggest a connection between inflammation and
lipid dysregulation in EOPE-associated newborns and a higher risk of cardiovascular diseases later in adulthood.
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Preeclampsia is a pregnancy-specific disease character-
ized by hypertension (blood pressure >140/90 mmHg)
and proteinuria (>0.3 g/day). It affects 5% to 8% of all
pregnancies [1] and is one of the leading causes of fetal/
neonatal and maternal morbidity and mortality [2]. Pre-
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unless otherwise stated.pregnancy, and depending on the time of the onset of
symptoms (earlier or later than 34 weeks), it can be cate-
gorized as early onset preeclampsia (EOPE) or late onset
preeclampsia (LOPE). Although EOPE and LOPE share
some clinical symptoms, they have distinct etiologies,
biochemical markers, and maternal and fetal outcomes
[3]. EOPE is considered a more severe, mostly fetal dis-
order, and it is typically associated with inadequate placen-
tal implantation and subsequent placental dysfunction,
intrauterine growth restriction, low birth weight, and
adverse maternal and fetal outcomes, including peri-
natal death. By contrast, LOPE is considered a maternal
disorder often associated with a normal placenta, larger
placental volume, normal fetal growth, and favorable
maternal and fetal outcomes. In this study, we focus on
EOPE given its severity.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that the process is initiated by the shallow implantation
of the placenta into the uterine wall [4]. During normal
pregnancy, extravillous trophoblasts remodel the spiral
arteries in the decidua lining during the formation of the
maternal placenta. However, in EOPE, such remodeling
is incomplete, leading to poor placental development
and function [5]. The incompletely transformed spiral
arteries are unable to provide an adequate blood supply to
the placenta, resulting in ischemia and hypoxic conditions,
which further lead to inflammatory stress, apoptosis, and
other phenomena in the trophoblasts [6-8]. In mothers,
the pathological manifestations of these conditions include
hypertension, thrombocytopenia, hemolysis, seizures,
acute atherosis, renal failure, and proteinuria [9-11].
Whereas in the fetus, the consequences include intrauter-
ine growth restriction and preterm delivery with associ-
ated issues such as neurodevelopmental disorders [12]
and long-term adult onset disorders including diabetes,
congestive heart failure, and hypertension [13].
Increasing evidence shows that epigenetic processes,
especially DNA methylation, play important roles in pre-
eclampsia [14]. While the majority of epigenetic studies
have been focusing on detecting differentially methylated
regions in the maternal blood [15,16] or placental tissues
[17-20], only a few studies have investigated the alteration
of local or global methylation and epigenetic factors in
neonatal cord blood cells associated with preeclampsia. At
the individual gene level, IGF2 but not GNAS has been
found to be significantly hypomethylated in cord blood
cells associated with maternal preeclampsia [21]. At the
global level, controversy exists regarding the plausible rela-
tionship between DNA methylation and preterm birth, a
major consequence of maternal EOPE. While some au-
thors have proposed that preeclampsia might epigenetically
program placental tissue but not umbilical cord blood [22],
others have found that preterm birth is associated with
overall lower LINE-1 methylation levels in cord blood,
which could be a surrogate of global DNA methylation
levels [23]. However, to our knowledge, there has been no
epigenome-scale methylation study on cord blood DNAs
in association with EOPE. In this study, we have for the
first time used the Infinium Human Methylation 450 KTable 1 The physiological and clinical parameters of study su
Parameters Case
Mother’s age (years) 30.5 ± 6.15
Gestational age (weeks)* 31.5 ± 2.15
Gravida 2.33 ± 1.78
Parity 1.00 ± 1.13
Baby’s weight (grams)* 1,350 ± 400
Gender 5 Female/7 male
*P < 0.05.BeadChip (450 K) to quantitatively analyze methylation on
over 485,000 CpG sites in the cord blood DNAs from
EOPE mothers (cases) and full-term controls. Our bio-
informatics and systems biology analyses have revealed a
global hypomethylation pattern in DNA extracted from
cord blood in infants born at <34 weeks due to EOPE and
have found many changes related to immune response and
cardiovascular dysfunction. The discovery could shed light
on the connection to adult-onset diseases in the newborns
from EOPE mothers.
Results
Global CpG hypomethylation in cord blood DNAs
associated with maternal EOPE
We compared the genome-scale methylation profile of
20 cord blood DNAs associated with maternal EOPE
cases and normal term delivery controls (12 cases vs. 8
controls). A summary of physiological and clinical fac-
tors associated with the maternal samples is tabulated in
Table 1, including mother’s age, gestational age, gravida,
parity, baby gender, and birth weight. We did not ob-
serve statistical differences in maternal age, gravida, par-
ity, and sex of babies between cases and controls. As a
consequence of EOPE, the patients had to deliver the
babies prematurely to terminate the potentially fatal
EOPE condition. Thus, both gestational age and mean
weight of the babies were significantly different between
EOPE and full-term controls (31.5 weeks versus
39.3 weeks, P = 2.28e − 8 and 1,350 g versus P = 1.17e − 9
and 3,420 g, respectively).
We first performed Principal Component Analysis
(PCA) with the M-values of the 384,632 pre-processed
methylation data points (Figure 1A). The cases were sep-
arable from the controls with the first three principal
components, indicating that the cord blood cell methyla-
tion data provide strong signatures to the maternal pre-
eclampsia condition. To systematically determine how
the physiological and clinical factors contributed to vari-
ance in the data, we performed analysis of variance
(ANOVA) and computed the average F-statistic for each
factor (Figure 1B). Given that gestational age and baby
weight differences are the direct consequences of EOPE
and thus they are highly correlated to EOPE, we use thebjects
Control P value
29.6 ± 5.15 0.7352
39.3 ± 0.49 2.28e − 8
2.75 ± 2.38 0.6794
1.12 ± 1.64 0.8544
3,420 ± 352 1.17e − 09
5 Female/3 male 0.4476084
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Figure 1 Global CpG hypomethylation in cord blood cells is associated with maternal preeclampsia. (A) 3D Principal Components Analysis
(PCA) of the methylation M-values from cord blood samples. Preeclampsia-associated cases are shown in red, while controls are in blue; PCA1, PCA2, and
PCA3 denote principal components 1, 2, and 3, respectively. The two groups are clearly separated when viewed using the first three principal components.
(B) ANOVA plot of clinical factors using the methylation M-values in cord blood samples. Averaged ANOVA F-statistics are calculated for potential
confounding factors, including preeclampsia, maternal age, gravida, parity, and baby gender. (C) Volcano plot of all CpG methylation M-values. The y-axis
of the negative log10 transformation of the P values obtained from differential methylation analysis of the CpG sites is plotted against the x-axis of the
difference in the average M-values between cases and controls. The dashed red line marks the α= 0.05 significance threshold after Benjamini-Hochberg
correction of multiple hypothesis tests (MHT), whereas the dashed black line marks the unadjusted α= 0.05 significance threshold.
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of these three factors. ANOVA analysis shows that pre-
eclampsia condition is the highest source of variance,
followed by parity and gravida. To determine the best
statistical model for the differential methylation (DM)
test, we used Akaike’s information criterion (AIC) to
compare the effects of physiological and clinical factors
on the linear model. The result shows that the model
with just preeclampsia had the best score and was se-
lected more often than the model containing parity and/
or gravida. We therefore conclude that maternal pre-
eclampsia is the primary source for the differences in
methylation among samples.
The DM analysis using a moderated t-test identified a
total of 64,049 significant CpG sites after the Benjamini-
Hochberg (BH) multiple hypothesis testing correction
with a threshold of P <0.05. A global hypomethylation pat-
tern was observed, with 51,486 hypomethylated sites and
12,563 hypermethylated sites (Figure 1C). To validate the
results of the Illumina 450 K array, we performed py-
rosequencing on seven selected CpG methylation sites
(cg26478401 from FAS, cg2607695 from PI3KR1,
cg06111286 from IL12B, cg06652329 from IGF1,
cg08198483 from miR-24-2, cg11671363 and cg08537847
from miR-145). A coefficient of correlation (R2) as high as
0.9387 (P < 2.2e − 6) was obtained by comparing the
methylation percentages determined by pyrosequenc-
ing and the β-values determined by Illumina 450 K
(Figure 2A). For individual CpG sites, the directions of
fold change in the 450 K compared to those of the pyrose-
quencing were consistent (Figure 2B, C, D, E, F, G, H),and the differences in pyrosequencing results between the
cases and controls were significant. These results show
the robustness and validity of the 450 K data.
Genome-scale patterns of differentially methylated CpG
sites in CpG islands and surrounding areas
To examine the methylation profile across genomic loca-
tions, we counted the number of DM sites, hypermethy-
lated sites, and hypomethylated sites in different genomic
categories relative to CpG islands (Figure 3A). The CpG-
related categories are based on the annotation given by
Illumina. CpG islands are defined as regions with a GC
content of 50% or greater, length greater than 200 bp and
with a ratio of observed CpGs to the expected number of
CpGs greater than 0.6 [24]. CpG shores are defined as 0
to 2 kb upstream (north) or downstream (south) of the
CpG islands and CpG shelves as 2 to 4 kb upstream or
downstream of the CpG islands. The open sea regions
refer to regions not located in any of the abovementioned
categories relating to CpG islands.
Significant differences between observed frequencies
and expected frequencies exist in all categories based on
CpG-related annotations as stated in the previous para-
graph (Figure 3A). The most striking result is the signifi-
cant (about fourfold) reduction in the percentages of the
overall DM and hypermethylated and hypomethylated
sites in the CpG islands compared to the background
percentage of probes in CpG islands (for example, the
percentage of all annotated probes in CpG islands). The
hypomethylation pattern is also evident in the heatmap
results of CpG islands with unsupervised hierarchical
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Figure 2 Technical validation of a set of DM CpG sites using pyrosequencing. (A) The overall correlation plot between the Beta values of seven
DM CpG sites obtained from Illumina HumanMethylation450 BeadChip array (y-axis) and methylation percentage from pyrosequencing (x-axis). Five case
and five control samples for each CpG site were selected for pyrosequencing validation. (B, C, D, E, F, G, H) Bar plots to compare the average Beta values
and pyrosequencing methylation percentage for individual CpG sites in (A): (B) cg26478401, (C) cg26076905, (D) cg11671363, (E) cg06111285,
(F) cg06652329, (G) cg08198483, and (H) cg08537847. Values are presented as mean± standard deviation (s.d.). The CpG sites that have significant P< 0.05
between cases and controls are labeled by (*).
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separated (Figure 4A). Conversely, there is significantly
more DM, including both hypermethylation and hypo-
methylation in the open sea region compared to the
background percentage (Figure 3A). The majority of
CpG islands are associated with gene promoters whereas
the open seas are often associated with gene body and
intergenic regions. These results show that methylation
changes in non-promoter regions of cord blood DNAs
are mostly associated with maternal EOPE (Figure 3B).
As examples, we selected the most statistically signifi-
cant 20 hypomethylated and 20 hypermethylated CpG
sites with an average β-value difference greater than 0.2
and present their dot plots in Additional file 1: Figure S1
and Additional file 2: Figure S2. The top three hyper-
methylated loci were cg03110921 (associated with DLG5),cg20968678 (associated with TMEM169), and cg14087413
(associated with TMEM8B). The top three hypomethy-
lated loci were cg18188328 (associated with JARID2),
cg02522196 (not associated with genes), and cg02291365
(not associated with genes). The dot plots have consistent
differential methylation patterns in these CpG sites be-
tween preeclampsia cases and controls.
Genome-scale patterns of differentially methylated CpG
sites in association with genes
According to the Illumina 450 K annotation, we catego-
rized the CpG sites in association with genes into seven
groups, namely the TSS1500 (200 to 1,500 bp upstream of
transcription starting sites), TSS200 (the transcription start-
ing sites to 200 bp upstream interval), 5′ UTR, first exon,
gene body, 3′ UTR, and intergenic regions. Significant
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Figure 3 Comparison of CpG site methylation of cord-blood-cell-associated EOPE and normal mothers. Distributions of all CpG site
categories on the Illumina HumanMethylation450 BeadChip array (background), all differentially methylated CpG sites, hypomethylated CpG sites,
and hypermethylated CpG sites. Categories with significantly different proportions (P < 0.05, Chi-square test) of differential CpG sites vs. expected
background (all CpG sites) are labeled by (*). Differences in categorical proportions between hypomethylation and hypermethylation are labeled
the same. (A) CpG site proportions by location relative to CpG isle regions. As stated in the “Results” section, six groups are categorized according
to Illumina 450 K annotation, namely north shelf, north shore, CpG island, south shore, south shelf, and open sea. (B) CpG site proportions by
functional location relative to gene regions. Seven groups are categorized, namely the 200 to 1,500 bp upstream of transcription starting site (TSS1500), the
transcription starting site to 200 bp upstream interval (TSS200), 5′ UTR, first exon, gene body, 3′ UTR, and the rest for integenic regions. DM, differential methylation.
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Figure 4 Heatmaps of DM CpG sites located in CpG islands (A) and the TSS200 region of genes (B). The rows correspond to CpG sites,
while the columns correspond to samples. Case samples are blue, and controls are green. The color of each cell in the heatmap is based on the
Beta (β) value of the corresponding CpG site in the corresponding sample, with colors ranging from red (β = 0) to blue (β = 1). The ordering of
CpG sites and samples in the heatmaps was determined via unsupervised hierarchical clustering.
Ching et al. Clinical Epigenetics  (2015) 7:21 Page 5 of 15
STAT4
GZMB
GADD45B
IL4
IFNGR1
GADD45G
SPOCK1
CCL2
TNF
CCBP2
IL23R
IL12B
IL12RB1 MMP17
SRGN
IL12RB2
ZNF467
TBX21
IL1B
IFNGR2
CSF1
IFNG
IL1RAP
GADD45GIP1
IL12A
IFNAR2
ETV5
HLX
CCL3
CXCL1
IL19
PLEKHM1
EOMES
SPARCL1
IL1R2
IL1RN
IL20RA
IL20A B
C D
Figure 5 Top networks in IPA and EpiMods analysis. (A) IPA network involved in the inflammatory response. (B) EpiMod validation network
containing genes involved in an immune/inflammatory process. (C) IPA network involved in cellular development, growth and proliferation, and
hematological system development and function. (D) IPA network involved in cell-to-cell signaling, hematological system development and func-
tion, and immune cell trafficking. Red and green colors represent hypermethylation and hypomethylation in the promoter of the
gene, respectively.
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are seen in all the seven CpG categories in association with
genes (Figure 3B). As expected from the annotations by
CpG island and surrounding areas, the most striking re-
sults are the significantly higher percentages of overall DM,
hypermethylated and hypomethylated sites in the gene
body and intergenic regions, compared to the background
percentage of probes located in these regions. Similar
results are also observed in the 3′ UTR. These results
highlight the significance of non-promoter-associated
differential methylation in EOPE. Consistent with the
observations in the CpG islands, we find that there is a
significantly lower percentage of DM and hypermethy-
lated and hypomethylated sites in the TSS200 and first
exon regions compared to their background probe per-
centages. The hypomethylation pattern in the TSS200
region is also evident in the heatmap results of CpGislands with unsupervised hierarchical clustering, where the
case and control groups are clearly separated (Figure 4B).
On the other hand, the TSS1500 regions have a signifi-
cantly lower percentage of hypomethylated sites but about
the same percentage of hypermethylated sites compared to
background percentages.
Promoter-associated network and pathway analysis
Given that methylation of CpG islands and promoter re-
gions have received the most attention in determining
how epigenetic changes affect gene expression [25,26],
we focused the rest of the analysis on the TSS200 region.
For each gene, we took the sum of the Beta values and
performed a DM test on the summed Beta values, using
a moderated t-test. As a result, 643 genes with hypo-
methylated promoters and 389 genes with hypermethy-
lated promoters were identified.
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(IPA) on the genes with significant DM at TSS200 to
identify pathways and networks that were altered in
EOPE (Figure 5A, C, D, Tables 2 and 3). The top five
networks were as follows: 1) inflammatory response, cellu-
lar function and maintenance, and respiratory disease; 2)
cellular development, cellular growth and proliferation,
and hematological system development and function; 3)
cell-to-cell signaling and interaction, hematological system
development and function, and immune cell trafficking; 4)
molecular transport, cellular movement, and hematological
system development and function; and 5) cellular develop-
ment, cellular growth and proliferation, and hematological
system development and function. Many genes previously
shown to be important in EOPE were found in these top
networks, such as PI3K1, FAS, IGF1, and IL12B. In
addition, several microRNAs appeared in the top five net-
works, such as mir-10a, mir-181c, mir-21, mir-101-1, and
mir-29a. Interestingly, the top canonical pathways were as
follows: (1) FXR/RXR activation, (2) granulocyte adhesion
and diapedesis, (3) altered T-cell and B-cell signaling in
rheumatoid arthritis, (4) hepatic cholestasis, and (5) agranu-
locyte adhesion and diapedesis.
We next used the software package EpiMod to validate
the network findings from IPA. Previously, EpiMod was
used to identify DM hotspots in the Illumina Infinium
27 K platform, by integrating methylation data with pro-
tein interaction networks using the methylation of
promoter-associated CpG sites [26]. We have extended
the package to include promoter-associated probes from
Illumina 450 K. Similarly to the IPA analysis, we used
the sum of Beta values within the TSS200 as the meas-
ure for DM, in order to perform the EpiMod analysis.
Many key genes in the EpiMod networks were also hubs
in the IPA network analysis, and the networks them-
selves were associated with many of the same functions.
We show one exemplary module from EpiMods with
the hotspot genes IL12B and receptors IL12RB1/B2
(Figure 5B). Similar to the best ranked network in IPA
(Figure 5A), this epi-module shows a clear enrichment
of genes involved in the inflammatory response. Consist-
ently, the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway enrichment analysis on the genes
found in this epi-module shows that “Cytokine-cytokine
receptor interaction” is the most significant pathway
(FDR = 2.5e − 21).
Differential methylation in the non-coding genomic
regions
Since more than 95% of the genome does not encode
proteins, we next examined the CpG sites in non-coding
RNAs. We first analyzed microRNAs, given that they are
relatively better understood compared to other non-
coding RNAs (ncRNAs). The microRNAs present in thetop ten IPA networks were grouped based on their
methylation status (hypo- vs. hypermethylation), and
their targets were predicted with the TargetScan pro-
gram. This list of target genes was then subjected to
KEGG analysis using the DAVID online functional anno-
tation tool [27]. Pathways with a BH-adjusted P value
less than 0.05 were considered significant. The pathways
that were enriched in the hypomethylated and hyper-
methylated microRNA target gene sets were similar, with
common signaling pathways such as the “ErbB signaling
pathway” and the “neurotrophin signaling pathway”
(Table 4). Other common biological processes such as
“endocytosis,” as well as diseases such as “Chronic mye-
loid leukemia” were also enriched.
We next predicted the function of various long inter-
genic non-coding RNAs (lincRNAs) that had DM in
TSS200 regions. In order to represent the protein-
coding genes with significant DM at the pathway level,
the summed β-values of the TSS200 regions of DM
protein-coding genes were used to generate a pathway-
based deregulation score matrix (PDS matrix). This
matrix is a measure of how much the activities of vari-
ous pathways deviate from normal. The summed β-
values of the TSS200 regions of DM lincRNAs were then
correlated with the scores in the PDS matrix using the
Spearman correlation coefficient (ρ). Only lincRNA-
pathway pairs that satisfied the cutoff absolute (ρ) >0.90
and P <0.05 are considered significant. A total of 96
KEGG and BIOCARTA pathways stand out, many of
which are related to the immune response and inflam-
mation [see Additional file 3: Table S2].
Tissue differences and genes of interest
We previously reported a global hypermethylation
coupled with hypomethylation in promoters from the
chorioamniotic membrane of EOPE patients [28]. Some
of the patients who participated in that study gave cord
blood samples for this study. To determine the contribu-
tion of tissue specificity vs. disease (EOPE) specificity,
we compared the subsets of methylation data from the
coupled chorioamniotic membrane and cord blood sam-
ples. An ANOVA model containing terms for pre-
eclampsia and the tissue type was used to gain insight
on their contributions. The resulting F-statistics show
that tissue type rather than EOPE is the dominant factor
responsible for the variance among the methylation data
[see Additional file 4: Figure S3].
We further analyzed the DM sites in both chorioamnio-
tic membranes and the cord blood, with moderated t-tests
subject to BH multiple hypothesis testing (MHT). The
analysis revealed that 10,510 CpG sites were considered
DM, and among them, 10,355 CpG sites were consistently
hypermethylated or hypomethylated in both tissues. These
sites were mapped to the TSS200 regions of 579 genes.
Table 2 CpG sites and genes of interest (significant CpG sites of interest)
CpG site Case mean Control mean P value (adjusted) Gene
cg05025071 1.040 −0.338 0.000 EMR1
cg02138358 1.432 0.359 0.000 MPO
cg16052198 −0.510 −1.522 0.000 FPR2
cg03633458 0.977 0.075 0.000 ELANE
cg21308575 −0.098 −1.172 0.000 EMR1
cg05094429 1.317 2.237 0.000 CCR6
cg12230709 0.068 −0.977 0.001 PRTN3
cg10161121 0.801 1.612 0.001 FASLG
cg06606386 −2.153 −3.251 0.001 MIR27A
cg16572540 0.012 −0.640 0.001 MIR24-2
cg07055315 0.326 −0.759 0.001 NLRC4
cg02515217 −0.141 1.510 0.001 MIR21
cg18447740 −0.352 −1.082 0.002 OSCAR
cg24964368 −0.331 −1.130 0.002 FPR2
cg08198483 −0.049 −0.769 0.002 MIR24-2
cg12123019 −0.681 −1.686 0.003 IL12RB1
cg17004025 0.052 −0.591 0.005 PRTN3
cg06100973 1.445 0.376 0.006 ELANE
cg05914150 2.411 1.611 0.006 PIK3R1
cg25341726 1.384 0.678 0.007 IL27
cg11582579 1.420 2.189 0.007 IL19
cg20660269a 0.303 −1.105 0.007 ADORA2A
cg04626878 −0.621 −1.509 0.013 PTK6
cg26149678 −0.592 −1.907 0.013 IL18BP
cg25091228 1.637 2.463 0.014 PIK3R1
cg10861599 −1.713 −2.283 0.015 TNFSF4
cg25756470 −2.031 −2.604 0.016 NCF4
cg14916288 −1.137 −1.756 0.022 CCL23
cg23763137 −0.032 −1.004 0.025 ADORA2A
cg16257983 −2.474 −3.092 0.026 FAS
cg11783497 0.522 1.625 0.026 IL1RN
cg08491125 −3.161 −3.864 0.027 ISG20
cg25247520 0.360 0.939 0.031 MIR1204
cg12929678 0.937 1.384 0.032 CD226
cg03974286 −0.676 −1.047 0.033 CFLAR
cg13747967 −1.309 −1.947 0.037 CCL22
cg01436254 0.913 0.439 0.042 CD86
cg00590039 −1.184 −1.738 0.043 TRAF3IP2
cg11201447 −0.109 0.567 0.043 MIR1204
cg13904968 0.567 1.788 0.044 PCK1
cg26394055 −0.293 −0.927 0.045 FCER1G
aThis CpG site is significantly hypermethylated by comparing to the results of Cruickshank et al. [32].
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Table 3 CpG sites and genes of interest (genes with significant TSS200)
Gene Case Control IPA network
CCL22 0.164 0.096 Inflammatory response, cellular function and maintenance, respiratory disease
CD86 1.014 0.875 Inflammatory response, cellular function and maintenance, respiratory disease
CFLAR 1.366 1.161 Inflammatory response, cellular function and maintenance, respiratory disease
FPR2 0.638 0.363 Inflammatory response, cellular function and maintenance, respiratory disease
IL19 1.545 1.727 Inflammatory response, cellular function and maintenance, respiratory disease
MPO 0.588 0.388 Inflammatory response, cellular function and maintenance, respiratory disease
NLRC4 0.696 0.471 Inflammatory response, cellular function and maintenance, respiratory disease
OSCAR 1.687 1.135 Inflammatory response, cellular function and maintenance, respiratory disease
PTK6 2.161 1.752 Inflammatory response, cellular function and maintenance, respiratory disease
TNFSF4 0.254 0.187 Inflammatory response, cellular function and maintenance, respiratory disease
TRAF3IP2 3.943 3.651 Inflammatory response, cellular function and maintenance, respiratory disease
CCL23 0.655 0.477 Cellular development, cellular growth and proliferation, hematological system development and function
CCR6 3.000 3.299 Cellular development, cellular growth and proliferation, hematological system development and function
FAS 1.226 0.865 Cellular development, cellular growth and proliferation, hematological system development and function
FASLG 1.294 1.566 Cellular development, cellular growth and proliferation, hematological system development and function
NCF4 0.766 0.532 Cellular development, cellular growth and proliferation, hematological system development and function
PIK3R1 3.526 3.337 Cellular development, cellular growth and proliferation, hematological system development and function
ADORA2Aa 1.879 1.077 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
CD226 1.384 1.554 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
ELANE 1.190 0.876 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
EMR1 1.146 0.699 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
FCER1G 0.176 0.105 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
IL27 1.105 0.856 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
IL18BP 5.765 4.816 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
IL1RN 1.998 2.652 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
ISG20 0.140 0.079 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
PCK1 1.725 2.310 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
PRTN3 0.911 0.637 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
MIR24-2 1.044 0.801 Inflammatory response, cellular development, tissue development
MIR1204 1.451 1.630 Inflammatory response, cellular development, tissue development
MIR21 1.736 1.911 Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking
MIR27A 0.279 0.217 Inflammatory response, cellular development, tissue development
aThis gene has significant methylation changes in the TSS200 related to gestational age, by comparing to the results of Cruickshank et al. [32].
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found among these 579 genes, including the highly con-
nected genes CD86, IL19, OSCAR, TRAF3IP2, FAS,
PIK3R1, IFNG, IL1RN, and ISG20. These results suggest
that a small number of genes involved in inflammation
and lipid metabolism are epigenetically modified similarly
in both membrane tissues and cord blood of fetal origin.
Discussion
Comparison with other cord blood methylation studies of
preeclampsia
Compared to the number of methylation studies in pla-
centa and maternal peripheral blood tissues related toEOPE, there are surprisingly few reports on umbilical
cord blood DNAs. This might be partially due to the fact
that EOPE is a maternal disease. However, given the
well-established link between preterm birth and adult-
hood onset diseases such as hypertension, cardiovascular
diseases, and obesity, it is plausible that some long-term
consequences are carried through the changes made by
“epigenetics markers” at or even before birth. In this
study, we describe in depth the significant genome-scale
hypomethylation observed in cord blood DNAs associ-
ated with maternal EOPE, based on the Illumina 450 K.
Our study confirms and expands on the very few earlier
methylation studies of cord blood samples from preterm
Table 4 Enriched KEGG pathways from predicted targets of top DM microRNAs
Count Percent of genes Fold enrichment P value (FDR)
Predicted targeted pathways of hypomethylated miRs
Glioma 45 6.42% 1.9269 0.0001
Axon guidance 77 10.99% 1.6102 0.0003
Pathways in cancer 166 23.69% 1.3653 0.0004
Endocytosis 101 14.41% 1.4808 0.0011
Insulin-signaling pathway 77 10.99% 1.5386 0.0040
ErbB-signaling pathway 54 7.71% 1.6744 0.0056
Neurotrophin-signaling pathway 71 10.13% 1.5446 0.0086
Chronic myeloid leukemia 47 6.71% 1.6905 0.0185
SNARE interactions in vesicular transport 28 4.00% 1.9877 0.0253
Predicted targeted pathways of hypermethylated miRs
Endocytosis 133 14.32% 1.4482 0.0000
MAPK-signaling pathway 178 19.17% 1.3357 0.0000
Neurotrophin-signaling pathway 92 9.91% 1.4865 0.0001
Axon guidance 95 10.23% 1.4755 0.0001
Pathways in cancer 211 22.73% 1.2889 0.0001
Chronic myeloid leukemia 59 6.35% 1.5761 0.0011
ErbB-signaling pathway 65 7.00% 1.4969 0.0061
Apoptosis 65 7.00% 1.4969 0.0061
Regulation of actin cytoskeleton 140 15.08% 1.3046 0.0074
Adherens junction 58 6.25% 1.5092 0.0147
Glioma 49 5.28% 1.5583 0.0196
Focal adhesion 130 14.00% 1.2958 0.0275
SNARE soluble NSF attachment protein receptor, MAPK mitogen-activated protein kinase.
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EOPE), which had either lower throughput or lacked
gene level resolution for DNA methylation. Burris et al.
used LINE-1 methylation levels as a surrogate measure-
ment of the global methylation and found that after ad-
justment for other confounding factors, a lower cord
blood LINE-1 level methylation was associated with a
shorter gestation (−0.45 weeks, (95% CI −0.83, −0.08))
and higher odds of preterm birth (OR 4.55 (95% CI 1.18,
17.5)) [23]. On the other hand, He et al. conducted a
pilot study to examine DNA methylation levels of IGF2
and GNAS in cord blood associated with preeclampsia.
They found that the average methylation level of IGF2
but not GNAS was significantly lower in the preeclamp-
sia samples [21]. We used a much higher throughput
method with the Illumina 450 K and also found that
IGF2 has one CpG site with a significantly lower methy-
lation level in the gene body (cg01668279, FDR adjusted
P = 0.0429). However, unlike the other study, we found
that seven out of nine CpG sites associated with GNAS
have significantly lower methylation in EOPE, in regions
ranging from the TSS1500 to the gene body. The overall
agreement between our study and the majority of otherstudies suggest that EOPE has broad effects resulting in
abnormal DNA methylation even in newborn cord blood
cells.
Potential complications in the study due to gestational
age and birth weight
In our current experimental design of comparing EOPE
vs. full-term delivery, earlier gestational age and lower
mean birth weights are naturally coupled with EOPE.
We considered EOPE as the major contributing factor of
DM, because the majority of the best-fit models have
EOPE as the only effective predictor. Also, the inclusion
of highly correlated factors in the statistical model, such
as gestational age and birth weight that are coupled with
EOPE, can inflate the standard error [29] and potentially
mask the causative effect of EOPE. Admittedly, these
two factors may confound the observed differences due
to EOPE. Hence, we compared our results with other
studies on the effect of gestational age on placental or
cord blood DNA methylation pattern without preeclamp-
sia [30-32]. Studies using cord blood show little evidence
of changes in methylation levels within the third trimester
[33,34]. In one study, Michels et al. found less than 1% of
Ching et al. Clinical Epigenetics  (2015) 7:21 Page 11 of 15effect comparing cord blood methylation of preterm ba-
bies to full-term babies [33]. In another study, Nomura
et al. found no significant effect on methylation due to
gestational age, in both placenta and cord blood (P = 0.31
and P = 0.82, respectively) [34]. In the placenta, the DNA
methylation pattern does change as gestation progresses.
However, the major changes of methylation occur from
the first to the second trimesters and considerably fewer
changes happen after the second trimester [31]. Moreover,
within the third trimester, the placental methylation pat-
terns from babies delivered earlier (around 34 weeks) and
those of full-term babies are clustered together and they
cannot be distinguished. This suggests that the gestational
ages within the last trimester have much less effect on the
placental DNA methylation. Novakovic et al. also stated
that the variation among samples in the third trimester
was primarily due to environmentally induced or stochas-
tic reasons. Altogether, these studies suggest that very
small or minimal differences in the observed methylation
patterns are due to gestational age in our study. This is
confirmed by Cruickshank et al. who found that only
1,555 DM sites from neonatal blood spots were statisti-
cally significantly associated with gestational age [32],
whereas we found 64,049 DM sites associated with EOPE
after MHT correction. Further, we compared the DM sites
in both studies and found that only 319 sites are com-
monly hypomethylated and 139 sites are commonly
hypermethylated [see Additional file 5: Table S3]. In sum-
mary, we conclude that gestational age and birth weight
have insignificant effect compared to the disease of EOPE.
Methylation changes related to inflammation
Evidence of changes in CpG methylation related to the
inflammatory process is strong in our data. In the top-
ranked IPA network (Figure 4A) and EpiMod module
(Figure 4B), we see that a large number of DM genes
(for example, IL12B, IL19, IL20, CCL2) are connected to
the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) complex, although NF-κB itself is
not differentially methylated. Although it is well known
that increased inflammatory stress exists in preeclampsia
placentas [35,36] and maternal tissues [37], little is
known about immunological responses in newborns.
Some studies have shown that Interleukin-6 (IL6) was
significantly elevated in the cord blood from neonates
born small with intrauterine growth retardation. How-
ever, no direct measurements of IL6 were made from
those born to preeclamptic mothers [38]. In another
study, the authors found evidence of higher NKp30
levels in NK cells, but not in the monocytes of cord
blood from preeclamptic pregnancies, suggesting that in-
flammatory responses may be cell-type specific [39].
Since we used the extracted genomic DNA from cord
blood cells without the purification of a subpopulation,the subpopulation-specific inflammation response in
EOPE could not be studied. However, we do know that
the DNA methylation changes occur in many genes in-
volved in inflammation. Meanwhile, we also observe that
some methylation differences are very interesting. For
example, the hyper-methylation of IL12B is validated by
our pyrosequencing, although the Beta value only de-
creases by 0.1 from 0.3 in cases (P < 0.05) (Figure 2E).
Corresponding to this finding, others reported that pre-
eclampsia patients had significantly less IL-12 in villous
trophoblasts [30], as well as significantly less IL-12 se-
cretion from the decidua [40]. Moreover, a positive cor-
relation between IL-12 and fetal birth weight in the
severe preeclamptic group was observed [40]. All the in-
formation seems to support the hypothesis that IL12B is
repressed at the gene expression level in the cord blood
cells. It will be very interesting to validate the IL12B
gene expression in fresh cord blood tissue.
Methylation changes related to potential cardiovascular
problems
Interestingly, we found that FXR/RXR activation and
hepatic cholestasis are among the top enriched pathways
in the IPA analysis of TSS200 DM regions. An important
target of FXR/RXR is fatty acid synthase, FAS [41],
which was consistently hypermethylated in both cord
blood and the placental chorioamniotic membrane. We
propose two hypotheses that could explain the methyla-
tion changes occurring in these pathways. One hypoth-
esis arises from the fact that fetal liver is the main
source of hemopoietic cells during the majority of the
gestational period [42]; thus, the DM related to FXR/
RXR activation and cholestasis in the cord blood cells
likely reflects the dysfunction of liver tissues of new-
borns associated with maternal EOPE. The nuclear re-
ceptors farnesoid X receptor (FXR) and liver X receptor
(LXR) form heterodimers with the retinoid X receptors
(RXRs) to regulate cholesterol and lipid metabolism, and
the primary tissue responsible for cholesterol metabol-
ism is the liver, where cholesterol biosynthesis occurs
and cholesterol low-density lipoprotein (LDL) is taken
up from the plasma by the LDL receptor. Another hy-
pothesis is that the DM observed in the FXR/RXR path-
way from the cord blood cells may be attributed to
circulating macrophages within the cord blood cells.
LXR/RXR dimers in macrophages activate ABC trans-
porters, such as ABCA1 and ABCG1, which efflux choles-
terol from macrophages and prevent toxicity due to
cholesterol accumulation [43]. In adults, macrophages
overloaded with cholesterol (or foam cells), are hallmarks
of atherosclerosis [44]. Regardless of the mechanism lead-
ing to the DM among genes related to FXR/RXR activa-
tion in cord blood cells, the FXR/RXR pathway is known
to play an important role in maintaining cholesterol
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be indicative of long-term risks for coronary heart disease
due to lipid metabolism dysfunction. Other processes,
such as the inflammatory stress mentioned earlier, might
also mediate or contribute to higher risks of cardiovascu-
lar diseases later in life for babies born to preeclamptic
mothers.
Future work
The samples in this study were obtained from the pre-
processed genomic DNA of cord blood cells stored in
the biorepository. As no cord blood serum was stored,
we could not obtain inflammatory molecule signals or
the lipid profiles in the cord blood. We plan to follow
up with another human study to validate the candidate
biomarker findings in the protein-coding genes and non-
coding RNAs at the methylation level and the expression
level.
Conclusions
To our knowledge, this study is the first to address the
genome-scale methylation changes in the cord blood
cells associated with EOPE patients. The newborn cord
blood cells are thought to originate from the fetal liver;
thus, much of the methylation changes involve signa-
tures of liver functions. We have found significant
genome-scale DNA methylation modifications that may
suggest a link between inflammation and lipid dysregula-
tion in newborns. These findings may suggest a link be-
tween maternal EOPE and newborns with an increased
lifetime risk of cardiovascular diseases.
Methods
Patient specimens
We utilized samples from the RMATRIX Hawaii
Biorepository (HiBR), which has obtained its own IRB
approval. From this repository, a total of 21 cord blood
samples were initially identified. Maternal cases had
EOPE at <34 weeks gestation and controls were full-
term pregnancies without preeclampsia. To ensure the
quality of the cord blood samples, maternal patients
with known medical or obstetrical disorders associated
with preeclampsia were excluded, including diabetes
mellitus or gestational diabetes mellitus, hypertension,
renal disease, hyperthyroidism, and systemic lupus ery-
thematous. Only singleton pregnancies were included.
DNA isolation
Genomic DNA from whole cord blood cells was extracted
by the HiBR laboratory. Clotted cord blood was centrifuged
through a Clotspin Basket (Qiagen) at 2,000 × g for 5 min
to disperse the clot. Three volumes of Red Blood Cell
(RBC) Lysis Solution (Qiagen) were added to one volume
of dispersed cord blood. The samples were briefly vortexed,shaken for 15 min at room temperature then centrifuged as
above to pellet leukocytes and clot particulates. The pellet
was resuspended in Cell Lysis Solution (Qiagen) containing
Proteinase K (Qiagen) at 20 mg/ml and then incubated at
55°C overnight. The Gentra Systems Autopure LS (Qiagen)
was used to extract the DNA from the sample using the
Compromised Cell Lysate Protocol. The purified DNA so-
lution was then incubated in a 65°C water bath for 1 h and
shaken at room temperature overnight.
Genome-scale methylome profiling using the
HumanMethylation450 BeadChip
Methylation profiling was done using the Illumina Infi-
nium methylation assay and the HumanMethylation450
BeadChip. First, the cord blood DNA samples were pre-
screened for the suitability of the Methylation450 assay
using Nanodrop to check the purity and the PicoGreen
assay to check the dsDNA concentration. The EZ DNA
Methylation kit was used for the bisulfite conversion
(Zymo Research), and 100 to 250 ng of bisulfite-
converted DNA was hybridized onto the Infinium Human
Methylation450 BeadChip following the Illumina Infinium
HD Methylation protocol.
Pyrosequencing validation
Primer design was carried out using the PyroMark Assay
Design 2.0 software. One of the primers was biotinylated
to enable capture by Streptavidin Sepharose. Bisulfite-
treated DNA was amplified followed by pyrosequencing
using the PyroMark PCR kit (Qiagen) on a PyroMark
Q24 instrument using PyroMark Gold Q24 Reagents, ac-
cording to the manufacturer’s protocol. The primers for
the seven CpG sites selected for validation are listed in
Additional file 6: Table S1.
Methylation data preprocessing
Raw data preprocessing was performed using the R
package “minfi” [45]. The background signal was sub-
tracted from the raw intensity data, and any probes with
a detection P value greater than 0.05 were eliminated.
The intensity value for each probe was transformed first
to methylation Beta values and then to M-values (the
logit transform of Beta values) and normalized using the
SWAN algorithm [46]. Probes with known SNPs based
on the latest annotation by Illumina were removed from
downstream analysis due to the concern that they could
confound intensity changes during later analysis steps.
Probes for CpG sites on sex chromosomes were removed
to eliminate the effect of the genders of newborns.
Site-level differential methylation (DM) analysis
Before DM analysis, samples were examined for the dif-
ferences using the primary physiological or clinical pa-
rameters. As a result, 12 cases (one case was eliminated
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determined suitable for DM. The AIC was used to select
the primary physiological or clinical parameters in a lin-
ear model that best explains the differences among the
methylation data. The model that optimized the AIC
score most frequently was the model with “preeclamp-
sia” as the only contributing variable. The importance of
this term was verified using ANOVA analysis, where the
preeclampsia factor was found to have the largest value
for its average F-statistic. A moderated t-test from the
“limma” package was used to determine the statistical
significance of difference in methylation for each CpG
site between cases and controls. The resulting P value
was then adjusted for MHT using the BH correction.
CpG sites with an adjusted P value less than 0.05 were
considered significant. Correlation heatmaps, PCA plots,
volcano plots, and bar graphs, and so on were generated
using R 3.0.2.
Ingenuity pathway analysis (IPA)
Since the promoter region plays a critical role in tran-
scriptional regulation, the sum of the Beta values of CpG
sites in the TSS200 region was used as a proxy for gene
methylation levels. The “limma” package’s moderated t-
test was used to determine the statistical significance of
methylation differences between cases and controls for
each gene. Similar to the site-level analysis, P values
were corrected for MHT using the BH correction, and
adjusted P values less than 0.05 were considered signifi-
cant. The log2-fold change in methylation values was
calculated, and values for significantly differentially
methylated genes were used as inputs to IPA to generate
gene interaction networks and canonical pathways that
are significantly associated with EOPE.
EpiMod analysis
Similar to the IPA analysis, the sums of Beta values for
sites in TSS200 regions were used as inputs for the func-
tions in the EpiMod package [26]. The EpiMod package
was originally developed to analyze Illumina 27 K data.
We modified the code to analyze 450 K data by re-
placing the methylation values of each gene with the
sum of TSS200, similar to the newer package Functional
Epigenetic Modules (FEM) from the same developers of
EpiMods [47].
Non-coding RNA methylation analysis
Two types of ncRNA were analyzed: microRNA and
lincRNA. TargetScan was used to predict mRNA targets
for the microRNAs that were found in the top ten IPA
networks. The microRNA targets were then subjected to
GO and KEGG analysis to determine the enriched gene
sets among the predicted targets. For lincRNA analysis,
the CpG sites were associated with annotated lincRNAsfrom the UCSC browser, and lincRNAs were tested for
differential methylation analysis in the TSS200 regions,
similar to the approach used for the protein-coding
genes described earlier (see the “Methods” section for
IPA analysis). To predict the function of differentially
methylated lincRNAs, the “pathifier” package was used
to create a PDS matrix [48], using the DM protein-
coding RefSeq genes per their sum of β-values in the
TSS200 region. Spearman’s rho (ρ) correlation coeffi-
cient was used to calculate the correlation between the
lincRNA methylation and the pathways built from DM
RefSeq genes in the samples. Pathway-lincRNA pairs
with |ρ| > 0.90 were kept for functional analysis.
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Additional file 1: Figure S1. Top 20 hypomethylated CpG sites. Dot
plots of statistically significant top 20 hypomethylated CpG sites with
Beta value difference greater than 0.2.
Additional file 2: Figure S2. Top 20 hypermethylated CpG sites. Dot
plots of statistically significant top 20 hypermethylated CpG sites.
Additional file 3: Table S2. LincRNA pathway analysis. KEGG and
BIOCARTA pathways with high correlations (ρ > 0.90) and significant
P values (P < 0.05) for lincRNAs.
Additional file 4: Figure S3. ANOVA plot of two factor analysis.
Average F-statistics plot of tissue and disease factors using the summed
TSS200 methylation Beta values in cord blood and paired chorioamniotic
membrane samples.
Additional file 5: Table S3. CpG sites related to preeclampsia and
gestational age. A list of CpG from a comparison of the differentially
methylated CpG sites in preeclampsia with the results of Cruickshank
et al. [32] on gestational age.
Additional file 6: Table S1. Pyrosequencing primers. A list of the
primer sequences used to validate important CpG sites.
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